Autism, nutrition, and functional medicine: what the evidence actually supports

Richard Moore
Apr 2
21 min read

The conversation autism care actually needs

If you are autistic, care for someone who is, or work clinically with neurodivergent individuals, you have probably come across advice that ranges from thoughtful to far more confident than the evidence warrants. Remove gluten. Heal the gut. Try this supplement stack. Support mitochondrial function. Reduce inflammation. Support methylation. For families and clinicians alike, the sheer volume of claims can become exhausting. It can also feel uncomfortable when the underlying message seems to be that autism is simply something to be corrected.

That is not a helpful starting point. Autism spectrum disorder (ASD) is a neurodevelopmental condition with strong genetic influences, considerable biological complexity, and wide variation in presentation, support needs, co-occurring symptoms, and lived experience (Bey et al., 2025; La Monica et al., 2025). It is not a disease in the conventional sense, and current evidence does not support the idea that it can be “cured” through diet, supplements, or microbiome manipulation. At the same time, that should not lead to the opposite mistake, which is ignoring the very real physical health issues that many autistic people experience, including gastrointestinal symptoms, food selectivity, sleep disturbance, nutritional insufficiencies, and anxiety-related physiological stress (Al-Beltagi et al., 2024; Conti et al., 2025).

This is where functional medicine enters the conversation. At its best, it asks sensible questions. What is making life harder than it needs to be for this person? Are there gastrointestinal issues, sleep problems, restricted eating patterns, inflammatory drivers, or nutrient shortfalls that can be identified and supported? At its worst, however, it drifts into oversized claims built on small studies, weak biomarkers, and the assumption that plausible biology automatically translates into effective treatment. In autism, that leap happens all the time.

So the real task is not to dismiss functional medicine outright, nor to embrace it uncritically. It is to look carefully at what the evidence actually shows, where it is genuinely promising, where it is still thin, and where common claims go beyond the data.

Autism is not one biological story

One of the main reasons autism research is so difficult to interpret is that autism is not a single biological entity. It is an umbrella diagnosis that includes different developmental trajectories, different symptom profiles, and different constellations of co-occurring challenges (Masi et al., 2017; Wang et al., 2025). Some autistic individuals have intellectual disability, some do not. Some have significant GI symptoms and highly restricted diets, while others do not. Some struggle mainly with sensory overload, anxiety, sleep disruption, and emotional regulation, while others present very differently (Al-Beltagi et al., 2024; Wang et al., 2025).

This helps explain why nutrition and supplement studies in autism often produce inconsistent results. A therapy that is useful for a subgroup with a particular metabolic or gastrointestinal profile may show little overall benefit when tested across a mixed population. Equally, a small positive study can look more impressive than it really is if the responder subgroup is not clearly defined, the outcomes are subjective, or the study is not well controlled (Rossignol & Frye, 2021; Zhang et al., 2025).

This is why broad claims are so often misleading in autism. The question is rarely “does this work for autism?” It is more often “might this help a specific subgroup, under specific conditions, for a specific outcome?”

What functional medicine may genuinely contribute

The most useful functional medicine lens in autism is not the promise of reversal. It is the willingness to look carefully at the terrain around the diagnosis. Is the person sleeping badly? Are they constipated? Are they bloated, uncomfortable, or alternating between diarrhoea and constipation? Are they eating a very narrow range of foods? Do they appear to be at risk of iron, vitamin D, folate, zinc, or omega-3 inadequacy? Are mealtimes full of stress, sensory distress, and conflict?

These are clinically relevant questions, and in many cases they are modifiable ones (Al-Beltagi et al., 2024; Conti et al., 2025). In practice, nutrition support in autism is often less about changing the core neurodevelopmental condition and more about reducing factors that add unnecessary strain to the system. Sometimes that means addressing constipation. Sometimes it means improving sleep. Sometimes it means widening food intake in a realistic, sensory-aware way. Sometimes it means identifying a genuine deficiency rather than assuming one.

That may sound less dramatic than some of the claims made online, but it is a much more honest reflection of where good care usually begins.

Food selectivity is not “just picky eating”

Food selectivity is one of the most important and most misunderstood clinical issues in autism. Eating patterns may be shaped by texture, smell, temperature, colour, predictability, anxiety, sensory overwhelm, interoceptive differences, previous digestive discomfort, or rigid preference for sameness, rather than simple fussiness or oppositional behaviour (Al-Beltagi et al., 2024; Conti et al., 2025). Calling it “picky eating” often misses the underlying picture entirely.

A 2025 systematic review found that food selectivity in autism was associated with increased risk of micronutrient deficiencies, gastrointestinal problems, eating disorder features, hypertriglyceridaemia, overweight, and obesity, although the authors also noted that the literature remains methodologically inconsistent because food selectivity is defined and measured differently across studies (Conti et al., 2025). A 2024 systematic review similarly concluded that feeding difficulties, food refusal, selectivity, and GI symptoms are common in autism, and that behavioural feeding support, gradual exposure, and supportive mealtime strategies may be just as important as supplements in real-world practice (Al-Beltagi et al., 2024).

That point matters. For many children and adults, the first useful intervention is not a long supplement protocol. It is a proper diet and symptom assessment, screening for likely deficiencies, and a feeding approach that respects sensory experience rather than treating it like defiance.

The gut-brain axis: important, plausible, and easy to oversell

If there is one area where functional medicine has influenced the wider conversation, it is in drawing attention to the gut. The gut-brain axis is a legitimate biological concept. It describes the continuous communication between the gastrointestinal tract and the brain through neural, immune, endocrine, and metabolic pathways, including microbial metabolites, vagal signalling, and the enteric nervous system (Cryan et al., 2019). In simple terms, the gut and brain are in constant conversation.

That matters in autism because gastrointestinal symptoms are common, and some studies suggest that greater GI burden may be associated with greater symptom severity in at least some subgroups (Al-Beltagi et al., 2024; Petropoulos et al., 2025). However, this is exactly where a plausible mechanism can be turned into an overconfident clinical story. Saying that gut-related mechanisms may contribute to symptoms in some individuals is not the same as saying autism is caused by gut dysbiosis. The first is a reasonable interpretation of current science. The second goes much further than the evidence allows.

A large 2024 study published in Nature Microbiology analysed faecal metagenomic data from 1,627 children and reported differences across bacteria, archaea, fungi, viruses, microbial genes, and metabolic pathways in autism, with a 31-marker microbial panel showing strong discrimination within that dataset (Su et al., 2024). It was a sophisticated and important paper, and one reason it drew attention is that it moved beyond the narrow bacteria-only lens that dominated much earlier microbiome work. Even so, it was observational. It identified associations, not causes. It also left open an important question: are these microbial patterns influencing symptoms, reflecting diet selectivity and altered eating behaviour, or both? (Su et al., 2024; Cryan et al., 2019).

A 2025 study in Nature Communications linked lower levels of certain tryptophan-related gut metabolites in autistic children to both autism symptom severity and altered activity in brain regions involved in interoception and emotional processing, including the mid-insula and mid-cingulate (Aziz-Zadeh et al., 2025). This is one of the more interesting recent human studies because it brings together metabolites, symptoms, and brain imaging within the same dataset. But it was still a cross-sectional case-control study. It tells us something potentially important about mechanism, but not yet whether changing that pathway will meaningfully improve clinical outcomes (Aziz-Zadeh et al., 2025).

Leaky gut: plausible mechanism, uneven human evidence

“Increased intestinal permeability” or “leaky gut” is often treated in functional medicine as though it is settled fact in autism. The proposed mechanism is straightforward: if the gut barrier becomes more permeable, bacterial products such as lipopolysaccharides may move into circulation, interact with immune pathways, and potentially contribute to systemic or neuroinflammatory signalling (De Angelis et al., 2018). Animal work has helped support biological plausibility. For example, a 2023 mouse study found that experimentally induced gut barrier dysfunction was associated with reduced social behaviour, which improved with metformin treatment (Kim et al., 2023).

However, human evidence is still mixed. Not all studies show abnormal intestinal permeability in autistic children, and symptom patterns alone are not enough to diagnose it confidently. So while the concept is biologically reasonable, clinicians should be careful about treating “leaky gut” as a universal explanation or as a diagnosis that can be assumed without robust evidence.

Neuroinflammation, oxidative stress, and mitochondria: real signals, but not the whole story

Several biological themes recur in autism research, including neuroinflammation, oxidative stress, and mitochondrial dysfunction. These mechanisms are attractive to functional medicine because they provide plausible targets for diet and supplementation, but they still require careful interpretation.

Neuroinflammation has been reported in postmortem, imaging, and peripheral biomarker studies, including evidence of microglial activation and raised inflammatory mediators such as interleukin-1, interleukin-6, and tumour necrosis factor alpha (Matta et al., 2019; Gevezova et al., 2023). Markers of oxidative stress have also been reported, alongside lower antioxidant capacity, suggesting that some autistic individuals may have a poorer balance between cellular wear and tear and the body’s ability to keep that damage under control, a bit like having more sparks flying than fire extinguishers available (Gevezova et al., 2023). A 2024 systematic review and meta-analysis of mitochondrial biomarkers also reported elevated lactate, pyruvate, and creatine kinase in autistic individuals, with some associations between these markers and clinical features including language delay, social difficulties, and gastrointestinal symptoms (Rossignol & Frye, 2024).

These signals are interesting, but they do not mean that every autistic person has mitochondrial disease, or that anti-inflammatory and antioxidant interventions will necessarily translate into large clinical benefits. In many papers, mechanistic plausibility is much stronger than intervention evidence. That distinction has to be held in mind throughout this field.

Probiotics, prebiotics, and microbiome-based therapies

This is one of the busiest and most confusing parts of the autism literature. Probiotics are widely used, especially when GI symptoms are present, and the rationale makes intuitive sense. If gut ecology influences symptom expression in some people, perhaps modifying the microbiome could help. The problem is that trial results remain inconsistent.

A 2024 updated meta-analysis reported significant improvement in behavioural symptoms with probiotic supplementation, while also emphasising the need for more personalised approaches and better evidence for efficacy and safety (Soleimanpour et al., 2024). By contrast, a 2025 systematic review and meta-analysis of gut microbiota-based therapies found that when autism was analysed specifically, the effect size was very small and not statistically significant, even though pooled effects across broader neurodevelopmental conditions looked somewhat more favourable (Sun et al., 2025). Another 2025 meta-analysis focusing on children with autism found non-significant overall effects on GI and behavioural symptoms, although longer treatment duration appeared somewhat more promising in subgroup analyses (Gao et al., 2025).

The most reasonable interpretation at this stage is that microbiome-based interventions may help some autistic individuals, especially where GI symptoms are prominent, but the overall trial signal is still modest and inconsistent. Strain selection, treatment duration, baseline symptom profile, and responder subgroups all remain important unresolved issues.

Faecal microbiota transplantation: fascinating, but not ready for routine care

Faecal microbiota transplantation (FMT) attracts attention partly because it sounds so dramatic, and partly because early studies were striking. A well-known open-label study using Microbiota Transfer Therapy, which combined antibiotics, bowel cleanse, acid suppression, and FMT in 18 autistic children, reported significant improvements in GI symptoms and autism-related behaviours that appeared to persist at two-year follow-up (Kang et al., 2019).

That is the sort of finding that can drive enthusiasm very quickly, but it also needs careful appraisal. The study was open-label and lacked a placebo control, which makes it vulnerable to expectancy effects, observer bias, and the difficulty of separating the microbiota intervention from the multiple co-interventions used alongside it. A later 2024 randomised, double-blind, placebo-controlled trial of oral FMT in children with autism found no significant improvement on the primary clinical outcome, although secondary analyses suggested some improvement in socialisation on the Vineland-3, a standard measure of everyday adaptive functioning and social development (Li et al., 2024).

This is a good example of why study design matters so much. The earlier results were more dramatic, but the later trial was methodologically stronger. It is also possible that route of delivery, participant selection, or intervention protocol influenced efficacy. At present, the fairest conclusion is that FMT remains an interesting research area, but not something that can yet be recommended confidently as routine autism care.

Diet interventions: where enthusiasm tends to outrun consistency

Gluten-free and casein-free diets

The gluten-free, casein-free (GFCF) diet has been discussed in autism for years. One proposed mechanism is that incomplete digestion of gluten and casein generates opioid-like peptides that influence behaviour, although this theory remains controversial. A 2022 systematic review and meta-analysis found that GFCF diets were associated with reductions in stereotypical behaviours and improvements in cognition in children with ASD, but the underlying trials were mixed, and not all randomised studies showed benefit (Keller et al., 2022).

That mixed picture matters. The evidence does not support a blanket recommendation that all autistic children should follow a GFCF diet. It is more plausible that some subgroups may benefit, particularly those with documented GI symptoms, food sensitivities, or specific dietary patterns that make such an approach relevant. Any elimination diet also carries nutritional risks if done poorly, especially where baseline diet variety is already limited.

Ketogenic diets

A more recent area of interest is the ketogenic diet. It has attracted attention because ketosis may influence inflammatory signalling, mitochondrial energy metabolism, neurotransmitter balance, and the gut microbiome, although much of that mechanistic discussion remains preliminary in autism rather than clinically established. Evidence in autistic children is still limited, and much of it comes from small studies, open-label trials, feasibility work, and reviews rather than large definitive randomised trials. A 2025 preprint reported that, in 62 children with ASD, a modified ketogenic diet was associated with greater improvement in Autism Behavior Checklist and Childhood Autism Rating Scale scores than the control condition, but as this paper has not yet been clearly published in a peer-reviewed journal, the findings should be interpreted cautiously. Ketogenic diets can also be difficult to implement and sustain in autistic children, especially where food selectivity and sensory-related eating rigidity are already present, and nutritional adequacy requires careful clinical supervision. At this stage, the ketogenic diet remains an interesting but still early-stage intervention that needs larger, peer-reviewed, multi-centre trials before broader conclusions can be drawn (Li et al., 2021; Albers et al., 2023; Liu et al., 2025).

Supplements: what looks promising, what looks modest, and what remains uncertain

Sulforaphane

Sulforaphane is one of the more interesting supplement candidates in autism. It has been studied because it affects redox signalling, cellular stress responses, and anti-inflammatory pathways, particularly through activation of Nrf2. A 2025 systematic review and meta-analysis of six randomised trials concluded that sulforaphane showed some potential to improve certain autism-related symptoms without a significant difference in adverse events, although many outcomes were not statistically significant and the authors advised cautious interpretation because of trial limitations including assessment tools, observer effects, and treatment duration (Wang et al., 2025). A landmark placebo-controlled trial in young men with moderate to severe autism also reported improvements in behaviour and social impairment after 18 weeks of treatment, with regression after discontinuation, suggesting a possible biological effect rather than a pure placebo response (Singh et al., 2014).

This is one of the more credible supplement stories in autism, but the trials are still relatively small and preparations vary across studies. It is promising, not settled.

Folinic acid and methylation-related pathways

Folinic acid is another area where the evidence is more interesting than many clinicians realise. A 2021 systematic review and meta-analysis concluded that cerebral folate deficiency and folate receptor alpha autoantibodies may be relevant in a subset of autistic children, and that folinic acid, a more readily usable form of folate also known as d,l-leucovorin, may improve verbal communication and other outcomes, particularly in those with impaired folate transport (Rossignol & Frye, 2021). A 2025 randomised clinical trial also found that high-dose folinic acid given over 12 weeks may improve developmental outcomes, with response appearing to vary according to folate metabolism gene polymorphisms (Zhang et al., 2025).

This is an area where personalised medicine thinking makes sense. The evidence does not suggest folinic acid is a universal autism treatment. It suggests there may be biologically defined subgroups in whom it is more relevant.

Vitamin D

Vitamin D deficiency is commonly reported in autistic populations, and supplementation has attracted understandable interest. A randomised placebo-controlled trial published in 2018 found symptom improvement in children with autism after four months of vitamin D supplementation (Saad et al., 2018). More recent work has also explored anti-inflammatory effects. However, evidence remains mixed, and vitamin D is better viewed as a nutrient that should be corrected when deficient, rather than as a primary autism treatment.

This distinction is also relevant prenatally. A large Danish trial found that higher-dose vitamin D supplementation during pregnancy was not associated with reduced autism risk in offspring, although higher baseline maternal vitamin D status was associated with lower risk, suggesting that correction of deficiency may matter more than indiscriminate high-dose supplementation (Molnár-Szentkirályi et al., 2024).

Omega-3 fatty acids

Omega-3 supplements are widely used, but the evidence is not as persuasive as many people expect. Some studies and meta-analyses suggest possible improvements in hyperactivity, stereotypy, or aspects of social communication, but overall findings are inconsistent and effect sizes are generally small (Doaei et al., 2021). Omega-3s may still be reasonable where dietary intake is poor or where there is another nutritional rationale, but they should not be presented as a major evidence-based treatment for core autism features.

NAC, magnesium, B6, zinc, carnitine, CoQ10

These supplements all have some degree of plausibility and some early supportive findings, but the evidence base is still patchy.

N-acetylcysteine (NAC), a precursor to glutathione, has been studied in autism for irritability, hyperactivity, social symptoms, and repetitive behaviours, with some encouraging findings, but the evidence remains mixed, dosing is not standardised, and the current trials are still too limited to support a broad recommendation (Lee et al., 2021; Nalbant et al., 2023).

Magnesium and vitamin B6 have been studied for decades. Some early trials reported improvements in social skills, non-verbal communication, and speech, but methodological limitations and small sample sizes make firm recommendations difficult (Mousain-Bosc et al., 2006).

Zinc deficiency appears relatively common in some ASD cohorts, but human intervention data remain limited. L-carnitine may be more relevant in specific metabolic subgroups, and a randomised trial reported improved Childhood Autism Rating Scale scores with supplementation (Geier et al., 2011). Ubiquinol has shown possible improvements in communication and sleep in a small study, but again the evidence base is preliminary (Gvozdjaková et al., 2014).

These are not necessarily ineffective interventions. The problem is that most of them sit in the zone of “possible, biologically plausible, but not yet established.”

Melatonin

Melatonin is one of the more clinically useful and evidence-supported tools in autism, particularly for sleep. A 2023 meta-analysis found that melatonin reduced sleep onset latency, reduced awakenings, and increased total sleep time in children with autism, although larger trials are still needed (Xiong et al., 2023). Given how strongly sleep disruption can affect emotional regulation, behaviour, family stress, and daytime functioning, this makes melatonin one of the more defensible symptom-targeted interventions currently available.

Broad-spectrum micronutrient formulas

Some researchers have tested comprehensive vitamin and mineral formulas rather than isolated nutrients. A randomised trial in 141 children and adults with autism found that a broad-spectrum supplement improved symptoms on the Aberrant Behavior Checklist more than standard medication and reduced self-injurious behaviour intensity (Adams et al., 2011). This approach has some logic because nutrient insufficiencies rarely occur in isolation, but replication and clearer subgroup identification are still needed.

Exercise may be one of the most underrated interventions

Exercise rarely gets the same attention as supplements, but it may be one of the most useful and lowest-risk interventions in this field. A 2024 systematic review and meta-analysis found that physical activity interventions improved sleep outcomes in autistic children and adolescents, including parent-reported sleep problems, sleep resistance, night waking, sleep duration, and actigraphy-measured sleep efficiency (Liang et al., 2024). A separate 2024 network meta-analysis found that sports games, combined exercise programmes, outdoor activity, and mind-body exercise improved sociability and communication outcomes to varying degrees (Kou et al., 2024).

That matters because sleep and emotional regulation are often central pressure points in family life. If a child sleeps better, many other domains may become easier to manage. Exercise is not a cure, but it may improve several overlapping areas at once, with a much better risk-benefit profile than many fashionable interventions.

Sleep hygiene still matters

Sleep is not a side issue in autism. It can influence appetite, emotional regulation, sensory tolerance, attention, behaviour, gut function, and the general stress level within the household. Alongside melatonin where appropriate, basic sleep support remains foundational. This includes predictable routines, reducing evening overstimulation, creating a sensory-appropriate sleep environment, and identifying contributors such as GI discomfort, anxiety, or dysregulated daily structure. A randomised controlled trial of telehealth-based parental support also found improvements in physical activity and sleep quality in autistic children, suggesting that practical family-level support can make a measurable difference (Ying et al., 2024).

Can autism be prevented? A sensitive question that needs careful language

This question needs care, both scientifically and ethically. Many autistic adults object, understandably, to the language of “prevention” because it can imply that autistic people themselves should not exist. At the same time, researchers are right to ask whether modifiable prenatal and early-life factors influence neurodevelopmental risk.

The current evidence does not support simplistic claims that autism can be prevented through one particular diet, supplement, or perfectly managed pregnancy. What it does suggest is that maternal nutrition and prenatal health matter. A 2025 umbrella review involving more than three million mother-offspring pairs found that maternal prenatal folic acid and multivitamin supplementation were associated with lower odds of autism in offspring, although the underlying evidence was observational and cannot prove causation (Abate et al., 2025). A 2024 study in JAMA Network Open found that higher prenatal diet quality scores were associated with lower autism-related trait scores in offspring, although diet quality is, of course, entangled with many other health and socioeconomic factors (Li et al., 2024).

There is also evidence that the timing of folate matters. Periconceptional folic acid intake, particularly from around four weeks before conception to eight weeks after, has been associated with reduced autism risk in some studies, which is biologically plausible given the importance of early neural development. But even here, the responsible conclusion is a cautious one: optimising maternal nutrition supports healthy neurodevelopment broadly. It does not justify guilt-based messaging that autism could be simply avoided if the “right” steps were taken.

Misconceptions that need to be cleared away

A few persistent misunderstandings still distort this field.

One is the idea that autism can be reduced to one root cause, whether that is inflammation, gut dysbiosis, toxins, methylation problems, or nutrient deficiency. Current evidence does not support a single-cause model. Autism appears to arise through a complex interaction of genetic and environmental influences, with multiple developmental pathways rather than one universal mechanism (Bey et al., 2025; La Monica et al., 2025).

Another is the belief that anecdotal improvement is the same as proof. The history of autism intervention includes many approaches that looked promising on the back of case reports or parent testimony but failed when tested more rigorously. This does not mean lived experience should be dismissed, but it does mean anecdotal reports should not be treated as equivalent to well-designed clinical evidence.

A further problem is the assumption that one protocol should work for everyone. If anything, the research points in the opposite direction. Precision matters. Subgroup biology matters. Baseline diet, symptom profile, sensory needs, gastrointestinal burden, and nutrient status all matter more than a generic supplement stack.

Where this leaves functional medicine in autism

The landscape in 2026 is neither hopeless nor revolutionary. The gut-brain axis is an important area of research. Some microbiome-based interventions may eventually prove useful for selected subgroups. Sulforaphane, folinic acid in specific contexts, melatonin for sleep, and possibly broad-spectrum micronutrient approaches are among the more interesting intervention areas. Exercise is probably underused. Prenatal nutrition matters for neurodevelopment. But none of that adds up to a simple protocol, and much of the field still suffers from small studies, weak blinding, inconsistent endpoints, publication bias, and commercial overstatement.

For autistic individuals, parents, and clinicians, that can feel frustrating. But it is still better than false certainty. Autism care does not need more overstatement. It needs careful science, respectful language, honest clinical reasoning, and support that improves quality of life without pretending to erase neurodivergence.

That may be less dramatic than some of the stories told online. It is also more likely to be true.

How You Nutrition Clinic can help

At You Nutrition Clinic, our approach is not to promise a cure or push a one-size-fits-all protocol. Instead, we look carefully at the issues that may be adding to day-to-day strain, whether that is gastrointestinal discomfort, restricted eating, poor sleep, likely nutrient insufficiency, or the practical challenge of building a realistic routine around food and lifestyle support.

For autistic children, adults, and families, that often means starting with the basics properly: taking a detailed case history, identifying symptom patterns, reviewing diet quality and food range, considering whether targeted testing is actually warranted, and making changes that are evidence-aware, practical, and individual. For clinicians, it means having a space to think critically about where nutrition may help, where the evidence is still emerging, and where caution is needed.

If you would like personalised support, You Nutrition Clinic can help you explore these questions in a way that is thoughtful, respectful, and grounded in the current evidence. Our Kids Clinic also works with children and teenagers, with a particular focus on autism, ADHD, ARFID, and selective eating.

To find out more and to arrange a free chat to see how we can help, please contact us at admin@younutritionclinic.com

🧩 Connect with us

For research updates, practical tips, and ongoing inspiration, follow us on Instagram:

👉 @nutritionandthebrain

👉 @younutritionkids

Stay curious. Stay hopeful. Support your brain. 🧠

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult with a qualified, registered medical doctor (MD) for diagnosis and treatment decisions.

References

Aagaard, K., Moos, T., Christesen, H. T., et al. (2024). High-dose vitamin D3 supplementation in pregnancy and risk of neurodevelopmental disorders in the children at age 10: A randomized clinical trial. The American Journal of Clinical Nutrition, 119(1), 88–97. https://doi.org/10.1016/j.ajcnut.2023.10.024

Abate, B. B., Dunstan, R. H., Trumble, S. J., Pase, M. P., & Oddy, W. H. (2025). The association between maternal prenatal folic acid and multivitamin supplementation and autism spectrum disorders in offspring: An umbrella review. PLOS ONE, 20(11), e0334852. https://doi.org/10.1371/journal.pone.0334852

Al-Beltagi, M., Saeed, N. K., Bediwy, A. S., ElMikkawy, D. M. E., Elkholy, M., Alsharif, M. E., & Bediwy, A. S. (2024). Nutritional management and autism spectrum disorder. World Journal of Pediatrics. Advance online publication.

Aziz-Zadeh, L., Mayer, E., Labus, J., Ringold, S., Jayashankar, A., Kilroy, E., Butera, C., Jacobs, J., Tanartkit, S., Joshi, S., & Dapretto, M. (2025). Relationships between brain activity, tryptophan-related gut metabolites, and autism symptomatology. Nature Communications, 16, 3465. https://doi.org/10.1038/s41467-025-58459-1

Barba-Vila, O., Carvajal, B., Granada, M. L., Ortega, M., Martínez de Alba, M., & Varea, V. (2025). Probiotics in autism spectrum disorder: a systematic review of clinical studies and future directions. Nutrition Reviews, 83(1), 58–74.

Conti, M. V., Fogliani, E., Neri, B., Cena, H., et al. (2025). Exploring the association between food selectivity and health outcomes in autism spectrum disorder: A systematic review. Nutrition Reviews. Advance online publication.

Cryan, J. F., O’Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., Guzzetta, K. E., Jaggar, M., Long-Smith, C. M., Lyte, J. M., Martin, J. A., Molinero-Perez, A., Moloney, G., Morelli, E., Morillas, E., et al. (2019). The microbiota-gut-brain axis. Physiological Reviews, 99(4), 1877–2013. https://doi.org/10.1152/physrev.00018.2018

De Angelis, M., Piccolo, M., Vannini, L., Siragusa, S., De Giacomo, A., Serrazzanetti, D. I., Cristofori, F., Guerzoni, M. E., Gobbetti, M., & Francavilla, R. (2018). The perturbance of microbiome and gut-brain axis in autism spectrum disorders. International Journal of Molecular Sciences, 19(8), 2251. https://doi.org/10.3390/ijms19082251

Friel, C., Francis, E., Hinkle, S. N., Ajjarapu, A. S., & Zhang, C. (2024). Healthy prenatal dietary pattern and offspring autism. JAMA Network Open, 7(7), e2421429. https://doi.org/10.1001/jamanetworkopen.2024.21429

Frye, R. E., Slattery, J., Delhey, L., Fett, B., Tober, R., Koenig, K., Ouyang, L., et al. (2018). Folinic acid improves verbal communication in children with autism and language impairment: A randomized double-blind placebo-controlled trial. Molecular Psychiatry, 23(2), 247–256. https://doi.org/10.1038/mp.2016.168

Gao, X., Zhang, Y., et al. (2026). A meta-analysis of the effects of gut microbiota-based interventions on gastrointestinal and behavioral symptoms in children with autism spectrum disorder. Nutrition Reviews. Advance online publication.

Gevezova, M., Sarafian, V., Anderson, G., & Maes, M. (2023). Neuroinflammation and oxidative stress in the pathogenesis of autism spectrum disorder. International Journal of Molecular Sciences, 24(6), 5487. https://doi.org/10.3390/ijms24065487

Kang, D.-W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., Pollard, E. L., Roux, S., Sadowsky, M. J., Lipson, K. S., Sullivan, M. B., Caporaso, J. G., & Krajmalnik-Brown, R. (2019). Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota. Scientific Reports, 9, 5821. https://doi.org/10.1038/s41598-019-42183-0

Keller, A., Rimestad, M. L., Friis Rohde, J., Petersen, B. H., Korfitsen, C. B., Tarp, S., Lauritsen, M. B., & Hoostø, A. (2022). Systematic review and meta-analysis of the benefits of a gluten-free diet and/or casein-free diet for children with autism spectrum disorder. Nutrition Reviews, 80(5), 1237–1246. https://doi.org/10.1093/nutrit/nuab065

Kotowska, M., et al. (2024). The impact of probiotics on core autism symptoms: A systematic review and meta-analysis of randomized clinical trials. Clinical Nutrition ESPEN, 63, 92–101.

Kou, R., Zhang, Y., et al. (2024). Comparative effectiveness of physical exercise interventions on sociability and communication in children and adolescents with autism: A systematic review and network meta-analysis. BMC Psychiatry, 24, Article 802.

La Monica, I., et al. (2025). Autism spectrum disorder: Genetic mechanisms and neurobiological underpinnings. International Journal of Molecular Sciences. Advance online publication.

Lee, T.-M., Lee, K.-M., Lee, C.-Y., Lee, H.-C., Tam, K.-W., & Loh, E.-W. (2021). Effectiveness of N-acetylcysteine in autism spectrum disorders: A meta-analysis of randomized controlled trials. Australian & New Zealand Journal of Psychiatry, 55(2), 196–206.

Liang, X., Haegele, J. A., Tse, A. C.-Y., Li, M., Zhang, H., Zhao, S., & Li, S. X. (2024). The impact of physical activity intervention on sleep in children and adolescents with autism spectrum disorder: A systematic review and meta-analysis. Sleep Medicine Reviews, 74, 101913. https://doi.org/10.1016/j.smrv.2024.101913

Matta, S. M., Hill-Yardin, E. L., & Crack, P. J. (2019). The influence of neuroinflammation in autism spectrum disorder. Brain, Behavior, and Immunity, 79, 75–90. https://doi.org/10.1016/j.bbi.2019.04.037

Nalbant, K., Demirel, Ö. F., & Aydın, A. (2023). Possible effects of N-acetylcysteine in autism spectrum disorder: A systematic review. Clinical Psychopharmacology and Neuroscience, 21(4), 674–689.

Nogueira, H. A., et al. (2023). Melatonin for sleep disorders in people with autism: A systematic review and meta-analysis. Developmental Medicine & Child Neurology, 65(7), 863–874.

Rossignol, D. A., & Frye, R. E. (2024). Biomarkers of mitochondrial dysfunction in autism spectrum disorder: A systematic review and meta-analysis. Neurobiology of Disease, 197, 106520. https://doi.org/10.1016/j.nbd.2024.106520

Su, Q., Wong, O. W. H., Lu, W., Wan, Y., Zhang, L., Xu, W., Li, M. K. T., Liu, C., Cheung, C. P., Ching, J. Y. L., Cheong, P. K., Leung, T. F., Chan, S., Leung, P., Chan, F. K. L., & Ng, S. C. (2024). Multikingdom and functional gut microbiota markers for autism spectrum disorder. Nature Microbiology, 9, 1704–1717.

Sun, W., Ma, L., Feng, X., Fan, Y., Cai, Y., & Li, X. (2025). Efficacy of gut microbiota-based therapy for autism spectrum disorder and attention deficit hyperactivity disorder: A systematic review and meta-analysis. Psychology, Health & Medicine. Advance online publication. https://doi.org/10.1080/13548506.2025.2565181

Talib, M., et al. (2024). The role of dietary patterns and nutritional supplements in children and adolescents with mental health problems: A meta-review. Nutrients.

Wan, L., Wang, H., Liang, Y., Zhang, X., Yao, X., Zhu, G., Cai, J., Liu, G., Liu, X., Niu, Q., Li, S., Zhang, B., Gao, J., Wang, J., Shi, X., Hu, L., Liu, X., Zou, Z., & Yang, G. (2024). Effect of oral faecal microbiota transplantation intervention for children with autism spectrum disorder: A randomised, double-blind, placebo-controlled trial. Clinical and Translational Medicine, 14(9), e70006. https://doi.org/10.1002/ctm2.70006

Wang, M., et al. (2025). Understanding autism: Causes, diagnosis, and advancing therapies. Neuropharmacology. Advance online publication.

Wang, R., et al. (2025). The effect of sulforaphane on autism spectrum disorder: Systematic review and meta-analysis. Frontiers in Psychiatry, 16, 1543904.

World Health Organization. (2025, December 11). WHO expert group’s new analysis reaffirms there is no link between vaccines and autism.

Xiong, M., et al. (2023). Efficacy of melatonin for insomnia in children with autism spectrum disorder: A meta-analysis. Neuropediatrics, 54(4), 252–262.

Zhang, C., et al. (2025). Safety and efficacy of high-dose folinic acid in children with autism: The impact of folate metabolism gene polymorphisms. Nutrients, 17(9), 1602. https://doi.org/10.3390/nu17091602